Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.47 |
| ▸ | GPR17 | Q13304 | 3/20 | 0.47 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.45 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.45 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.41 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17605302 | 0.86 | ALDH1A1 (0.39) | FFAR1GPR17SLC22A12AKR1B1AKR1B10 | |
| SCHEMBL15379086 | 0.81 | PARP1 (0.49) | FFAR1GPR17PTGER1PTGER4PTGER3 | |
| SCHEMBL1627280 | 0.81 | AKR1B1 (0.57) | AKR1B1KMT2AAKR1B10UGT1A9TRPA1 | |
| SCHEMBL4699564 | 0.81 | TAAR1 (0.55) | FFAR1GPR17PTGER1PTGER4PTGER3 | |
| SCHEMBL455219 | 0.81 | FFAR1 (0.59) | FFAR1PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL30288127 | 0.81 | FFAR1 (0.59) | FFAR1PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL27503091 | 0.80 | FFAR1 (0.48) | FFAR1GPR17PTGER1PTGER4PTGER3 | |
| Hydrochloric Acid SCHEMBL16239236 | 0.79 | FFAR1 (0.58) | FFAR1PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL22089619 | 0.79 | FFAR1 (0.47) | FFAR1GPR17PTGER1PTGER4PTGER3 | |
| SCHEMBL22102586 | 0.79 | FFAR1 (0.47) | FFAR1GPR17PTGER1PTGER4PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180193315-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC (US) | 2018-07-12 | — | — | US | disclosed |
| US-20180071262-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2018-03-15 | — | — | US | disclosed |
| US-20160235716-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2016-08-18 | — | — | US | disclosed |
| WO-2016044770-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160235716-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, HDAC9 | FFAR1 2557/4885GPR17 4684/4885PTGER1 1192/4885 |
| US-20180193315-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, KAT2A | FFAR1 2543/4885GPR17 4689/4885PTGER1 1294/4885 |
| US-20180071262-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, HDAC9 | FFAR1 2557/4885GPR17 4684/4885PTGER1 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.